Urinary System Inflammatory Disorders – Study Notes

Urinary Tract Infections (UTIs)

• Definition and normal defenses

  • Kidneys, ureters, bladder and proximal urethra are normally sterile.
  • Sterility is maintained by: frequent flushing of urine; secretory antibody (IgA) in bladder lining.
  • Distal urethra has a microbial community consisting of:
  • Gram-positive bacteria (e.g., Staphylococcus epidermidis)
  • Gram-negative bacteria (e.g., Escherichia coli)

• UTI risk factors

  • Patient-related factors
  • Own bowel flora; bacteria from faeces; can be carried by bloodstream from a distal infection (haematogenous spread).
  • Age-related factors: bladder dysfunction, urinary and faecal incontinence, low oestrogen.
  • Obstruction: kidney stones block flow of urine and can cause urinary reflux; incomplete voiding reduces flushing action.
  • Metabolic factors: diabetes elevates urine glucose levels and ↓ immune function.
  • Hospital-related factors
  • Urological instrumentation such as catheterisation.
  • Gender differences
  • Females are about $30\times$ more likely to develop a UTI than males.

• Main pathogens

  • Most common cause of community- and hospital-acquired UTIs: $Escherichia\ coli$ (E. coli).
  • Catheterised patients
  • Short-term: often caused by endogenous organisms (patient’s own flora).
  • Long-term: often caused by exogenous organisms (instruments/equipment, transfer from nurse’s hands).

• Clinical manifestations by site

  • Urethritis: E. coli attaches to urethral epithelial cells, damages urethral lining → inflammation.
  • Cystitis: E. coli ascends to bladder, attaches to bladder epithelium, damages lining via cell apoptosis and shedding → inflammation; symptoms include dysuria, increased frequency and urgency.

• Diagnosis

  • Ward assessment: odor, colour, and cloudiness; dipstick for blood and nitrates.
  • Mid-stream urine sample: laboratory findings include neutrophils, high concentration of bacteria, nitrates, and possibly blood.
  • Referenced figure: Fig. 16.9 (p.190) supports diagnostic features.

• Management

  • Indwelling catheter: removal or replacement often leads to resolution.
  • Initial management: broad-spectrum antibiotic while awaiting culture results.
  • Common antibiotics used: $\text{Co-trimoxazole}$, $\text{Nitrofurantoin}$, $\text{Fluoroquinolones}$.
  • Adjunctive measures: encourage fluid intake to flush bacteria; urinary alkalisers and multiple warm baths may reduce dysuria; cranberry derivatives may reduce bacterial adhesion to epithelial lining.

• UTI overview (summary points)

  • Main defences against infection; key role of IgA in bladder mucosa.
  • Highest risk in females; catheterisation increases risk via exogenous organisms.
  • Diagnosis via dipstick and urine culture; management centers on antibiotics and hydration.

Pyelonephritis

• Definition and pathophysiology

  • Pyelonephritis means infection and inflammation of the kidney. The elements:
  • 'pyelo-' pelvis; 'nephr-' kidney; '-itis' inflammation.
  • Infection usually begins in the urethra and bladder and ascends to the tubules of the nephrons in the medulla and may reach the cortex and glomeruli.
  • Most common microbe involved: $Escherichia\ coli$.
  • Acute pyelonephritis may be accompanied by phagocytes and inflammatory exudate moving from blood into the affected area, obstructing tubule function; can result in swelling, pus formation, and bleeding; in severe cases, infection may spread to the bloodstream causing sepsis.
  • Chronic pyelonephritis results from persistent/repeated infections or obstructive conditions, causing gradual damage and replacement of functional tissue with scar tissue; risk factors include urinary obstruction, urinary stasis, and urinary reflux. Often asymptomatic until irreversible tissue loss leading to chronic kidney disease.

• Acute pyelonephritis (acute)

  • Spread mechanism: microorganisms ascend the ureters from lower urinary tract.
  • Pathophysiology: phagocytes and inflammatory exudate impede tubule function; obstruction may occur; pus and bleeding may develop.
  • Systemic complication: infection may spread to the bloodstream causing sepsis.

• Chronic pyelonephritis (chronic)

  • Recurrent infections or chronic obstruction (e.g., kidney stones) cause progressive inflammation and loss of functional tissue.
  • Structural changes: altered renal pelvis and calyces, destruction of tubules, and diffuse scarring.
  • Functional consequence: impaired urine concentration; progression to chronic kidney disease (CKD).
  • Clinical risk factors: urinary obstruction, urinary stasis, urinary reflux.

• Clinical manifestations

  • Acute pyelonephritis: dysuria, increased frequency and urgency, flank pain, high fever, tachycardia.
  • Chronic pyelonephritis: diffuse flank pain; other UTI symptoms may be absent; potential for sepsis with hypotension and tachycardia if acute on chronic process.
  • Notable imaging/reference features: acute pyelonephritis may show pale abscesses (Fig. 16.11).

• Diagnosis and treatment

  • Diagnostic approach: urinalysis; blood tests if sepsis suspected; imaging to rule out other causes.
  • Management: antibiotic therapy; relief of obstruction in chronic cases; analgesics and fever control; ensure adequate hydration; manage sepsis with appropriate meds, IV antibiotics, fluids, and critical care transfer if needed.
  • Reflux-related considerations: urinary reflux may be evaluated via imaging (Fig. 16.12).

• Review takeaway

  • Understand the pathophysiology, clinical manifestations and management of both acute and chronic pyelonephritis.

Glomerulonephritis and Glomerulosclerosis

• Glomerulonephritis (GN)

  • Definition: a group of conditions characterized by inflammation of the glomerulus.
  • Pathophysiology: alteration in the epithelial layer of the glomerular capillary membrane changes permeability, leading to a reduced glomerular filtration rate (GFR) and a risk of acute kidney injury (AKI).
  • Clinical classification: often based on clinical presentation; GN typically involves loss of protein in urine (proteinuria) and/or blood in urine (hematuria) depending on syndrome type.
  • Syndromes
  • Nephrotic syndrome: excessive protein loss in urine (proteinuria).
  • Nephritic syndrome: associated with blood loss in urine (hematuria).
  • Examples
  • Membranous glomerulonephritis (nephrotic)
  • IgA nephropathy (Berger’s disease) (nephritic)

• IgA nephropathy (Berger’s disease)

  • Very common GN form; IgA is important in mucosal immunity.
  • Immune reaction triggers release of altered IgA into blood; natural immunoglobulins bind to IgA forming large immune complexes.
  • Deposition of immune complexes in the glomerulus activates an acute inflammatory process (glomerulonephritis).
  • Consequences: reduced filtrate leads to ↓ GFR and urine volume; inflammation increases glomerular permeability, allowing blood cells and large proteins into urine; plasma protein concentration falls, reducing osmotic pressure at capillaries, causing edema.

• GN pathogenesis (general)

  • Deposition of circulating antibodies or antigen–antibody complexes.
  • Activation of the complement system on injured glomerular epithelial cells.
  • Release of inflammatory mediators by mesangial and epithelial cells.
  • Result: increased glomerular membrane permeability, thickening of the glomerular membrane, and glomerulosclerosis.

• Acute post-streptococcal glomerulonephritis (APSGN)

  • A classic GN example caused by throat or skin infection with Group A Streptococcus.
  • Immune response is type III hypersensitivity; immune complexes formed are trapped in the glomerulus.
  • Inflammatory response reduces GFR and urine output, contributing to AKI.

• Acute versus chronic GN

  • Acute GN: may occur without prior kidney disease history; may progress due to secondary damage from hyperlipidaemia and proteinuria to glomerulosclerosis and interstitial injury.
  • Chronic GN: progression toward chronic kidney disease (CKD) with ongoing glomerular and tubular injury.

• Glomerulosclerosis pathogenesis

  • Diffuse scarring of the glomerular capillaries impedes filtration and causes ischaemic damage to kidney cortex and medulla.
  • Pathogenesis factors
  • Chronic hypertension: systemic hypertension → intraglomerular hypertension and hyperfiltration (↑ GFR).
  • Diabetic mellitus/diabetic nephropathy: high glucose → microvascular damage; protein denaturation → structural changes in the glomerulus; glomerular enlargement, basement membrane thickening, and cell proliferation.
  • Mechanistic sequence (simplified): damage to small arteries/arterioles → inadequate nephron blood supply → decreased glomerular blood flow → sclerosis → remaining nephrons hyperfiltrate to compensate → further glomerular damage and protein loss (
    proteinuria) and hypoalbuminaemia.

• Consequences of glomerulosclerosis

  • Proteinuria
  • Hyperlipidaemia
  • Increased susceptibility to infection (loss of antibodies and complement proteins)
  • Hypoalbuminaemia
  • Edema
  • Kidney failure

• Clinical manifestations (GN spectrum)

  • Hypertension and headaches
  • Edema
  • Haematuria
  • Proteinuria
  • Oliguria (< $400\,\mathrm{mL/day}$)
  • Flank pain
  • Skin rashes
  • Nausea, vomiting, anorexia

• Management strategies

  • For streptococcal GN: antibiotics against streptococci.
  • Oedema: fluid restriction and loop diuretics.
  • Hypertension: antihypertensives and loop diuretics.
  • Oliguria or anuria: dialysis may be needed.
  • Overactive immune response: corticosteroids.

• Summary takeaway

  • GN involves immune-mediated inflammation of glomeruli with potential progression to glomerulosclerosis and CKD; glomerulosclerosis itself results from hemodynamic and metabolic stresses (notably hypertension and diabetes) leading to protein loss, oedema, and renal failure.

Acute Tubular Necrosis (ATN)

• Definition and epidemiology

  • ATN is the damage and death of epithelial cells lining the nephron tubules; it is the most common cause of acute kidney injury (AKI).

• Aetiology (causes)

  • Ischaemia due to hypoperfusion (e.g., shock, sepsis, dehydration).
  • Direct damage from nephrotoxins (e.g., radiology contrast dye used in CT scans).
  • ATN is frequently reversible; recovery may take up to $21\text{ days}$.
  • Massive cell death without replacement leads to kidney impairment.

• Pathophysiology (how ATN develops)

  • Reduced blood supply (ischaemia) or exposure to nephrotoxins.
  • Hypoxia causes proximal tubule epithelial cell necrosis.
  • Sloughing off of tubular endothelial cells leads to obstruction and increased intraluminal pressure.
  • Tubuloglomerular feedback induces afferent arteriolar vasoconstriction and reduces glomerular filtration rate (GFR).

• Clinical manifestations

  • Presentation varies with cause:
  • Ischaemia from hypovolaemic shock: hypotension, tachycardia, oliguria.
  • Ischaemia from sepsis: same as above plus fever or rash.
  • Diagnosis indicators:
  • Physical examination findings.
  • Urinalysis: muddy brown, granular casts.
  • Blood tests: elevated urea and creatinine.
  • Imaging: ultrasound/CT/MRI to rule out other causes.

• Management

  • Tailored to the underlying cause:
  • Ischaemic ATN: support volume and blood pressure to aid recovery.
  • Nephrotoxic ATN: remove the offending toxin; use protective strategies when contrast media is involved.
  • Additional supportive measures:
  • Diuretics to promote urine output if appropriate.
  • Haemodialysis if required.
  • Correct hyperkalaemia and acidosis if they develop.

• Tubulointerstitial nephritis (brief mention from the slide)

  • Types include drug-induced and immune-complex-mediated; systemic infection can elicit hypersensitivity reactions.
  • Pathophysiology involves inflammatory mediators and vasoconstriction in the medullary vessels leading to papillary ischaemia and papillary necrosis in severe cases.
  • Acute symptoms may include arthralgia, sterile pyuria, nausea, rash; chronic symptoms can include colicky pain and fever.
  • Three-phase clinical snapshot (Initiation, Maintenance, Recovery) describes the evolution from hypoperfusion and ATP depletion to tubular obstruction, then recovery with improving GFR.

• Clinical takeaway

  • ATN remains the most common cause of AKI; early identification and removal of nephrotoxins, hemodynamic support, and renal replacement therapy when indicated are critical for recovery.

Review and Connections

• UTIs, pyelonephritis, GN/glomerulosclerosis, and ATN represent a spectrum of urinary system inflammatory and injury processes ranging from localized mucosal infection (UTI) to systemic inflammatory kidney injury (GN) and acute tubular injury (ATN).

• Key connections

  • Bacterial infections (E. coli) can initiate UTIs that ascend to cause pyelonephritis, which may lead to CKD if recurrent or untreated.
  • GN and glomerulosclerosis involve immune-mediated damage to glomeruli, with potential progression to CKD and AKI depending on severity and chronicity.
  • Hypertension and diabetes are central drivers of glomerulosclerosis and its renal consequences (proteinuria, edema, hypoalbuminaemia, CKD).
  • ATN often results from systemic illness or nephrotoxins in critically ill patients and can complicate other kidney disease processes by compounding renal injury.

• Practical implications

  • Early diagnosis and treatment of UTIs (antibiotics, hydration) can prevent ascent to pyelonephritis.
  • Recognition of GN signs (proteinuria, hematuria, edema, hypertension) prompts evaluation for immune-mediated causes and potential corticosteroid therapy.
  • Management of CKD risks (hypertension, glycemic control in diabetes) is essential to slow progression of glomerulosclerosis.
  • In AKI settings, avoidance of nephrotoxins and prompt hemodynamic optimization are critical to prevent ATN progression.

• Formulas and numeric references (LaTeX)

  • UTI risk factor increase in females: $30\times$ higher risk than males.
  • Oliguria threshold: < 400\ \mathrm{mL/day}.
  • Recovery time for ATN: up to $21\ \text{days}$.
  • Oliguria threshold for GN: < 400\ \mathrm{mL/day}.
  • GFR and filtration concepts are discussed in context; refer to figures for detailed paraclinical relationships (e.g., Fig. 16.11–16.16 across GN/Glomerulosclerosis sections).

• References to figures (for study familiarity)

  • Fig. 16.1, 16.2, 16.4: anatomy and flow of urine.
  • Fig. 16.3: UTI distribution in kidney/urinary tract.
  • Fig. 16.5–16.6: UTI risk factors.
  • Fig. 16.7: UTI pathophysiology and management concepts.
  • Fig. 16.9: UTI diagnostic indicators.
  • Fig. 16.11: acute pyelonephritis imaging example.
  • Fig. 16.12: Urinary reflux imaging.
  • Fig. 16.14: Glomerulonephritis schematic.
  • Fig. 16.16: Glomerulosclerosis schematic.
  • Fig. 16.17: ATN initiation/maintenance/recovery phases (tubulointerstitial nephritis context).

• References (course readings)

  • Acharya et al. 2020; Carlson & Clapperton 2025; Bullock & Hales 2024; Craft et al. 2023; Marieb & Hoehn 2023; Paul et al. 2017.

Key definitions to memorize

• UTI: Infection of the urinary tract with local symptoms (dysuria, frequency, urgency) and sometimes systemic signs.
• Pyelonephritis: Infection/inflammation of the kidney, often ascending from lower urinary tract; can cause sepsis if spread to the bloodstream.
• Glomerulonephritis: Inflammation of the glomeruli; may present with proteinuria and/or hematuria depending on the nephrotic or nephritic syndrome.
• Glomerulosclerosis: Diffuse scarring of glomerular capillaries leading to ischaemia and CKD; driven by hypertension and diabetes among other factors.
• ATN: Acute tubular necrosis; epithelial injury to nephron tubules due to ischaemia or nephrotoxins; common cause of AKI; recovery can take weeks.